NurOwn, a cell-based therapy that protects and helps repair nerve cells, also may be able to curb the damaging brain inflammation that contributes to the progression of amyotrophic lateral sclerosis (ALS), recent findings suggest.
Researchers believe this newly-found potential may extend the benefits of NurOwn in ALS patients and possibly among those with other conditions.
The findings were to be presented at the 2020 American Academy of Neurology (AAN) annual meeting, in April, but the meeting was canceled due to the COVID-19 pandemic. The poster, “MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells,” was published in an online supplement of the journal Neurology.
